# Monopar Therapeutics

Source: https://onco.cc/companies/monopar/  
OnCo record `monopar` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Monopar is a Chicago-area biotech that took the mucositis drug validive into a phase 3 trial in head and neck cancer, which failed in 2023, and now develops radiopharmaceuticals against the uPAR protein.

## Summary

Monopar Therapeutics, based in the Chicago area, developed validive (clonidine mucobuccal tablet) to prevent severe oral mucositis in patients having chemoradiotherapy for oropharyngeal cancer; the phase 3 VOICE trial did not meet its endpoint in 2023. The company has since focused on MNPR-101, an antibody against the urokinase receptor uPAR, as an imaging agent and radiotherapeutic, and on a Wilson disease programme. Its trials are registered on ClinicalTrials.gov under Monopar as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Monopar Therapeutics Inc.; Monopar
- Tags: ctgov-sponsor
- HQ: Chicago, IL
- Type: biotech
- Website: https://www.monopartx.com

## Sources

- Official website: https://www.monopartx.com
- ClinicalTrials.gov: trials led by Monopar Therapeutics Inc.: https://clinicaltrials.gov/search?lead=Monopar%20Therapeutics%20Inc.

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/monopar.json